SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:0eba5f86-2ab0-430d-823f-618d499e7b85"
 

Search: onr:"swepub:oai:lup.lub.lu.se:0eba5f86-2ab0-430d-823f-618d499e7b85" > The Impact of Quadr...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years

Wheeler, Cosette M. (author)
Kjaer, Susanne K. (author)
Sigurdsson, Kristjan (author)
show more...
Iversen, Ole-Erik (author)
Hernandez-Avila, Mauricio (author)
Perez, Gonzalo (author)
Brown, Darron R. (author)
Koutsky, Laura A. (author)
Tay, Eng Hseon (author)
Garcia, Patricia (author)
Ault, Kevin A. (author)
Garland, Suzanne M. (author)
Leodolter, Sepp (author)
Olsson, Sven-Eric (author)
Karolinska Institutet
Tang, Grace W. K. (author)
Ferris, Daron G. (author)
Paavonen, Jorma (author)
Steben, Marc (author)
Bosch, F. Xavier (author)
Dillner, Joakim (author)
Karolinska Institutet,Lund University,Lunds universitet,Klinisk mikrobiologi, Malmö,Forskargrupper vid Lunds universitet,Clinical Microbiology, Malmö,Lund University Research Groups
Joura, Elmar A. (author)
Kurman, Robert J. (author)
Majewski, Slawomir (author)
Munoz, Nubia (author)
Myers, Evan R. (author)
Villa, Luisa L. (author)
Taddeo, Frank J. (author)
Roberts, Christine (author)
Tadesse, Amha (author)
Bryan, Janine (author)
Lupinacci, Lisa C. (author)
Giacoletti, Katherine E. D. (author)
James, Margaret (author)
Vuocolo, Scott (author)
Hesley, Teresa M. (author)
Barr, Eliav (author)
show less...
 (creator_code:org_t)
Oxford University Press (OUP), 2009
2009
English.
In: Journal Of Infectious Diseases. - : Oxford University Press (OUP). - 0022-1899 .- 1537-6613. ; 199:7, s. 936-944
  • Conference paper (peer-reviewed)
Abstract Subject headings
Close  
  • Background. We evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) associated with >20% of cervical cancers. The population evaluated included HPV-naive women and women with preexisting HPV infection and/or HPV-related disease at enrollment. Methods. Phase 3 efficacy studies enrolled 17,622 women aged 16-26 years. Subjects underwent cervicovaginal sampling and Pap testing on day 1 and then at 6-12-month intervals for up to 4 years. HPV typing was performed on samples from enrollment and follow-up visits, including samples obtained for diagnosis or treatment of HPV-related disease. All subjects who received >= 1 dose and returned for follow-up were included. Results. Vaccination reduced the rate of HPV-31/33/45/52/58 infection by 17.7% (95% confidence interval [CI], 5.1% to 28.7%) and of cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS) by 18.8% (95% CI, 7.4% to 28.9%). Vaccination also reduced the rate of HPV-31/58/59-related CIN1-3/AIS by 26.0% (95% CI, 6.7% to 41.4%), 28.1% (95% CI, 5.3% to 45.6%), and 37.6% (95% CI, 6.0% to 59.1%), respectively. Although a modest reduction in HPV-31/33/45/52/58-related CIN2 or worse was observed, the estimated reduction was not statistically significant. Conclusions. These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6, -11, -16, and - 18. Long-term monitoring of vaccinated populations are needed to fully ascertain the population-based impact and public health significance of these findings.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Publication and Content Type

kon (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view